Looking for cancer markers in self-collected urine and vaginal samples for gynecological cancers
Studies markers in self-collected samples from adults with gynecological cancers or postmenopausal bleeding.
Plain-language title generated from the registry record
Registry title: Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Key facts
- Where
- Edegem, BelgiumSee the site
Where in Belgium
- University Hospital of Antwerp (UZA)Edegem, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universiteit Antwerpen
- Trial code
- NCT07902375
- Record updated
- 6 November 2026
- Original description
The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial, ovarian, vulvar, or vaginal (pre-)cancer or to postmenopausal bleeding. Samples collected by clinicians from the cervix or vulva, as well as blood and tissue samples, will be used for comparison. The study will explore whether these markers could help improve earlier and less invasive detection of gynecological cancers in the future.Read full original descriptionShow less
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in self-collected samples, such as first-void urine and vaginal samples, are linked to the presence of endometrial, ovarian, vulvar, or vaginal (pre-)cancer or to postmenopausal bleeding. Samples collected by clinicians from the cervix or vulva, as well as blood and tissue samples, will be used for comparison. The study will explore whether these markers could help improve earlier and less invasive detection of gynecological cancers in the future.
Inclusion: Individuals having female genital organs, regardless of their gender identity; 18 years old or older at the time of signing the informed consent form; Diagnosed with either endometrial, ovarian, vulvar, or vaginal cancer irrespective of stage; diagnosed with one of their precursor lesions; or individuals with postmenopausal bleeding; Has not started any form of cancer treatment prior to study enrolment; Written informed consent must be obtained from each participant; The participant is able to understand the information brochure and what the study is about.
Exclusion: Treatment for endometrial, ovarian, vulvar, or vaginal (pre-)cancer in the last 6 months before participation in the study; Participating in another interventional clinical study (where, e.g., a medical device, drug, or vaccine is evaluated) at the same time as participating in this study. Participation in another observational or low-interventional clinical study at the same time is allowed; The participant received a blood transfusion two weeks before sample collection; Participants with a history or current evidence of any condition or abnormality that might confound the results of the study, or when it is not in the best interest of the participant to participate, in the opinion of the investigator; Individuals that underwent hysterectomy or ovariectomy; Pregnant individuals or 6 weeks post-partum; Unable to give informed consent; The participant has severe anemia.